Novo Nordisk Ziltivekimab ZEUS Trial headline results were officially released on 31 July 2026 by Novo Nordisk from Bagsværd, Denmark (Company Announcement No 45 / 2026). The randomized, double-blind, placebo-controlled Phase 3 study evaluated once-monthly subcutaneous ziltivekimab 15 mg versus placebo on top of standard of care in more than 6,300 adults living with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and persistent systemic inflammation measured by high-sensitivity C-reactive protein.
Ziltivekimab is an investigational, fully human monoclonal antibody designed to bind to and inhibit the interleukin-6 (IL-6) ligand, a central driver of vascular inflammation. Throughout the trial, ziltivekimab successfully achieved targeted biological inhibition of the IL-6 pathway, which was confirmed by expected reductions in circulating free IL-6 and hsCRP levels. However, this downstream anti-inflammatory activity did not result in a statistically significant reduction in major adverse cardiovascular events (MACE) compared to placebo.
Primary endpoint evaluations from the Novo Nordisk Ziltivekimab ZEUS Trial demonstrated a Cox regression hazard ratio (HR) of 0.99 (95% confidence interval: 0.88 to 1.11) for the full analysis set in-study primary endpoint. The trial evaluated time to first occurrence of 3-point MACE, defined as cardiovascular death, non-fatal heart attack (myocardial infarction), or non-fatal stroke. Martin Holst Lange, executive vice president, chief scientific officer, and head of Research and Development at Novo Nordisk, stated that while ziltivekimab produced its intended biological mechanism, it did not achieve MACE risk reduction in this patient population, providing critical scientific insights for the ongoing cardiovascular research pipeline.
Safety Profile and Pipeline Strategy in the Novo Nordisk Ziltivekimab ZEUS Trial
Safety evaluations in the Novo Nordisk Ziltivekimab ZEUS Trial demonstrated that overall rates of adverse events (AEs) and serious adverse events (SAEs) among participants treated with ziltivekimab were comparable to those in the placebo group. Consistent with the mechanism of IL-6 pathway inhibition, a higher proportion of individuals in the ziltivekimab arm experienced serious infections compared to placebo, while no difference in all-cause mortality was observed between treatment arms.
Despite the outcome of the ZEUS trial, Novo Nordisk confirmed that two additional ongoing cardiovascular outcomes trials investigating ziltivekimab will proceed as scheduled. These include the HERMES trial in patients with heart failure (specifically heart failure with preserved ejection fraction) and the ARTEMIS trial in patients following an acute myocardial infarction (heart attack). Both studies remain on track to read out in the first half of 2027, as highlighted in official updates on ziltivekimab clinical trials.
From a financial standpoint, the outcome of the trial will not affect Novo Nordisk’s previously communicated 2026 adjusted operating profit outlook. However, a non-cash impairment charge will be recognized in the third quarter of 2026, with full detailed trial results set to be presented at an upcoming scientific conference in 2026. Official company announcements can be directly verified via the Novo Nordisk Press Release Portal.
